{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"16"}]}],"title":"Treatment-Emergent ADA (n=599, 598)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"16"}]}],"title":"Follow-Up Emergent ADA (n=506, 481)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"599"},{"groupId":"OG001","value":"598"}],"units":"Participants"}],"description":"The number of participants who had treatment-emergent or follow-up emergent anti-drug antibodies (ADA) is reported. Participants with treatment-emergent ADA were defined as participants who had any sample from baseline through Cycle 5 pre-infusion that was a 4-fold increase (2 dilution increase) in immunogenicity titer over the baseline titer, or participants who tested negative at baseline and positive post-baseline (at titer of ≥1:20). Participants with follow-up emergent ADA were defined as participants who had any sample during 30 days post last infusion that was a 4-fold increase (2 dilution increase) in immunogenicity titer over the baseline titer.","groups":[{"description":"On Day 1 of each 21-day cycle, participants received ramucirumab DP followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\n* Ramucirumab DP: 10 mg/kg administered intravenously.\n* Docetaxel: 75 mg/m\\^2 (60 mg/m\\^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously.","id":"OG000","title":"Ramucirumab and Docetaxel"},{"description":"On Day 1 of each 21-day cycle, participants received placebo followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\n* Placebo (matching Ramucirumab DP): 10 mg/kg administered intravenously.\n* Docetaxel: 75 mg/m\\^2 (60 mg/m\\^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously.","id":"OG001","title":"Placebo and Docetaxel"}],"paramType":"NUMBER","populationDescription":"Randomized participants who received any quantity of study treatment, grouped by the treatment they actually received, who had a baseline and at least 1 post-baseline ADA assessment.","reportingStatus":"POSTED","timeFrame":"Baseline, prior to infusion for week 4 and 8 (cycles 3 and 5), and 30 days following last infusion (up to Cycle 38, 21 days/cycle)","title":"Number of Participants With Anti-Ramucirumab Antibodies","type":"SECONDARY","unitOfMeasure":"participants"}